You are here: Industry Insights > Verastem

News List

Verastem Oncology with Breakthrough Therapy for Defactinib in Ovarian Cancer americanpharmaceuticalreview
May 28, 2021
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile.
Verastem to divest Copiktra rights to Secura Bio for up to $381m pharmaceutical-technology
August 12, 2020
Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial and development rights for Copiktra (duvelisib) to Secura Bio in a deal valued at up to $381m.
Verastem Oncology announces new strategic direction to advance its clinical development programmes pharmaceutical-business-review
March 06, 2020
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer ...
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility firstwordpharma
April 24, 2019
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility...
Relay adds executives to its chemistry, R&D teams as it transitions to the development stage fiercebiotech
January 02, 2019
Former Fierce 15 winner Relay Therapeutics has brought on Verastem’s Mahesh Padval, Ph.D., and Eli Lilly’s Mary Mader, Ph.D., to boost its drug discovery and development operations in oncology as it begins to transition to an R&D-stage biotech.....
US clears Verastem’s Copiktra for blood cancers pharmatimes
September 27, 2018
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small...